Vifor Pharma (SIX Swiss Exchange:VIFNI) (SIN:CH0364749348) disclosed on Monday that it has agreed to acquire the priority review voucher (PRV) from US Food and Drug Administration (FDA).
The company stated that the PRV entitles the holder to obtain priority review for a New Drug Application or Biologics License Application thereby reducing the target review time and potentially leading to a faster approval.
This transaction is subject to customary closing conditions and clearance under the Hart-Scott Rodino (HSR) Antitrust Improvements Act.
Headquartered in Switzerland, the pharmaceuticals company is engaged in iron deficiency, nephrology and cardio-renal therapies. It said it strives to help patients around the world with severe and chronic diseases to lead better, healthier lives.
Sebela's MIUDELLA Hormone-Free Copper IUS recognised in TIME's best inventions of 2025
Merck reports positive Phase 3 data for investigational two-drug HIV regimen doravirine/islatravir
60 Degrees reports first patient has tested negative for babesiosis in tafenoquine study
Minovia Therapeutics' MNV-201 receives FDA Orphan Drug Designation for Myelodysplastic Syndrome
BeOne Medicines' sonrotoclax receives FDA Breakthrough Therapy Designation for MCL
Ascletis selects once-monthly SQ GLP-1R/GIPR dual peptide agonist, ASC35, for clinical development
Celltrion's biosimilar EYDENZELT (aflibercept-boav) approved by US FDA
Rigel Pharmaceuticals begins dose expansion phase of R289 study in lower-risk MDS
Precision NeuroMed's glioblastoma multiforme treatment granted FDA Orphan Drug Designation
Merck completes acquisition of Verona Pharma to expand cardio-pulmonary portfolio